Hoth Therapeutics
We are committed to the patient experience by following the science to develop impactful and versatile treatment solutions for everyone. At HOTH, we stand by our mission to innovate today for a better tomorrow.
Learn more about our therapeutic areas, Early Access program, as well as ongoing and future clinical trial opportunities.
If you have questions regarding our clinical trials, please contact us here.
Current Development
HT-004
Asthma
HT-004 is an Antisense oligonucleotide (ASO) under development for treatment of IgE-mediated allergies and asthma maintenance therapy. HT-004 targets FcεRIβ via alternative splicing. Alternative splicing results in non-functional FcεRIβ that lacks the first two transmembrane regions, rendering it incapable of trafficking FcεRIα to the plasma membrane (and not activating inflammatory response). Early research stage (lead candidate optimization) – humanized mouse model studies are in progress.
HT-VA
Obesity
HT-VA is a glial cell line derived neurotrophic factor (“GDNF”) being developed for the treatment of obesity and obesity-related diseases and conditions. A GDNF family receptor alpha-1 (GFRα-1) agonist, important for the differentiation and survival of neurons, GDNF signals through its receptors, including Ret and GFR-1α, by activation of the PI3K and MAPK pathways. HT-VA is being formulated to treat or prevent obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising of one or more GDNF receptor agonists.